A routine surveillance test by the Veterinary Authority on farming site A-73
Hvannasund Norður has resulted in suspicion of fish being infected by pathogenic
ISA-virus. The suspicion arose after the result in one cage indicated that the
fish is infected by the so called HPR-del ISA-virus.
Bakkafrost is preparing to take necessary actions.
The Veterinary Authority will carry out further tests in this cage and all other
cages in the farming site. The results of these tests will be available over the
next few days.
Farming site A-73 Hvannasund Norður contains 1.2 million fish with an average
weight of approximately 0.54 kg whole fish equivalent (wfe). Total biomass is
approximately 665 tonnes wfe.
The farming companies and the authorities on the Faroe Islands have put a lot of
work into maintaining the good biological status in the Faroe Islands. Regular
surveillance tests for ISA-viruses have been performed at all farms during the
last approximately 12 years in sea sites in the Faroe Islands.
Bakkafrost expects to send out a stock announcement, when the final results from
the tests on farming site A-73 Hvannasund Norður are available and conclusion is
made regarding future actions.
Contacts:
Regin Jacobsen, CEO of P/F Bakkafrost: +298 23 50 01 (mobile)
Gunnar Nielsen, CFO of P/F Bakkafrost: +298 23 50 60 (mobile)
This information is subject of the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.
About Bakkafrost:
Bakkafrost is the largest salmon farmer in the Faroe Islands. The Group is fully
integrated from feed production to smolt, farming, VAP and sales. The Group has
production of fishmeal, fish oil and salmon feed in Fuglafjørður. The Group
operates licenses on 14 farming fjords. The Group has primary processing in
Klaksvík, Strendur, Kollafjørður, and secondary processing (VAP) in Glyvrar and
Fuglafjørður. The headquarter is located in Glyvrar, and the company has a total
of around 725 full-time employees.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES.
This press release does not constitute or form part of an offer or solicitation
to purchase or subscribe for securities. The securities referred to herein may
not be offered or sold in the United States absent registration or an exemption
from registration as provided in the U.S. Securities Act of 1933, as amended.
Copies of this announcement are not being made and may not be distributed or
sent into the United States, Australia, Canada or Japan.